Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03910738 (ClinicalTrials.gov)	October 29, 2019	1/4/2019	TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis	TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Nebido ® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection;Drug: Placebo 4 mL Solution for Injection;Procedure: MRI;Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities;Behavioral: Assessment of disability	University Hospital, Strasbourg, France	Bayer;Fédération Hospitalo-Universitaire NEUROGENYCS	Recruiting	18 Years	55 Years	Male	40	Phase 2	France
2	NCT03000127 (ClinicalTrials.gov)	July 1, 2018	17/12/2016	Testosterone for Fatigue in Men With MS	A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis	Multiple Sclerosis	Drug: AndroGel 1 % Topical Gel;Drug: Placebos	University of California, Los Angeles	Washington University School of Medicine	Withdrawn	18 Years	60 Years	Male	0	Phase 2	United States
3	NCT02317263 (ClinicalTrials.gov)	December 2014	3/12/2014	A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis		Multiple Sclerosis	Drug: testosterone;Drug: placebo gel	University of California, Los Angeles	NULL	Withdrawn	18 Years	60 Years	Male	0	Phase 2	NULL
4	NCT01516554 (ClinicalTrials.gov)	February 2012	19/1/2012	Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients	A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients	Multiple Sclerosis;Fatigue	Drug: Testosterone undecanoate;Drug: placebo	Health Sciences Centre, Winnipeg, Manitoba	University of Manitoba;Consortium of Multiple Sclerosis Centers;Manitoba Medical Service Foundation	Terminated	18 Years	65 Years	Male	3	Phase 2	Canada
5	NCT00405353 (ClinicalTrials.gov)	April 2002	28/11/2006	Testosterone Treatment for Multiple Sclerosis	Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial	Multiple Sclerosis	Drug: Androgel 10 grams of gel containing 100 mg of testosterone	University of California, Los Angeles	National Multiple Sclerosis Society	Completed	18 Years	65 Years	Male	10	Phase 1/Phase 2	United States

先頭へ